ATXN1L Inhibitors
ATXN1L, an abbreviation for ataxin 1 like, is a protein characterized by its ability to enable DNA and RNA binding activity. Functioning primarily in the nucleolus and nucleoplasm, this protein plays pivotal roles in various cellular processes. One of its primary responsibilities includes regulating transcription in a DNA-templated manner. Additionally, ATXN1L has demonstrated involvement in learning, memory, and certain aspects of social behavior. Its capacity to influence lung alveolus development, exert negative regulation on transcription by RNA polymerase II, and promote hematopoietic stem cell proliferation underscores its multifaceted nature. The dual capability to bind both DNA and RNA accentuates its central position in the orchestration of cellular gene expression and its associated processes.
Inhibitors targeting ATXN1L generally act by indirectly influencing the protein's function, given the broad spectrum of ATXN1L's responsibilities. Many of these inhibitory compounds exert their effects by interacting with the transcriptional and RNA processing machinery of the cell. By interfering with the transcriptional dynamics, such inhibitors alter the environments in which ATXN1L operates, thereby modifying its function. Additionally, some compounds are known to disrupt protein-DNA or protein-RNA interactions, which could indirectly challenge ATXN1L's binding efficacy. Another subclass of these inhibitors modulates the splicing dynamics, thereby altering the nature and structure of RNA molecules within the cell, which could subsequently influence the interactions of RNA-binding proteins like ATXN1L. Given the intricacies of cellular processes, a holistic understanding of how these inhibitors work necessitates considering the broader transcriptional and translational landscape, along with the myriad of interactions that converge to determine the functional outcomes of proteins like ATXN1L.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Alpha-amanitin exerts its effect by binding to the RNA polymerase II enzyme, leading to its inhibition. Given ATXN1L's RNA binding properties, there's a theoretical possibility that the disruption of RNA synthesis could impact ATXN1L's function at the transcriptional level. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
By intercalating into DNA, Actinomycin D disrupts the DNA-dependent RNA synthesis process. As ATXN1L possesses DNA binding activity, the presence of Actinomycin D could hinder ATXN1L's ability to interact with its DNA targets. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) inhibits RNA polymerase II, potentially influencing post-transcriptional modifications. This inhibition might lead to altered RNA structures, which could indirectly impede ATXN1L's RNA binding function. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide inhibits the XPB subunit of the TFIIH complex, potentially altering the transcriptional landscape. By modifying the transcriptional milieu, it could indirectly influence the environments in which ATXN1L functions. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
As a cyclin-dependent kinase (CDK) inhibitor, Flavopiridol may impact transcriptional processes. This interruption of the cellular transcription machinery could conceivably modulate the operational contexts for ATXN1L. | ||||||
THZ1 | 1604810-83-4 | sc-507542 | 1 mg | $95.00 | ||
THZ1 covalently inhibits CDK7, influencing the broader transcriptional machinery. Such alterations in transcriptional dynamics could have a ripple effect, influencing proteins like ATXN1L involved in RNA or DNA interactions. | ||||||
Isoginkgetin | 548-19-6 | sc-507430 | 5 mg | $225.00 | ||
This biflavonoid impedes pre-mRNA splicing. Given that splicing can influence the secondary and tertiary structures of RNA, the introduction of Isoginkgetin might indirectly modify the RNA substrates ATXN1L interacts with. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Targeting several kinases, Ibrutinib might bring about transcriptional changes. While its direct interaction with ATXN1L isn't established, any alterations in the transcriptional environment might conceivably impact ATXN1L's function. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
As a splicing inhibitor, Pladienolide B could influence the quality and nature of RNA molecules within the cell. This could create an indirect effect on ATXN1L's ability to interact with certain RNA substrates. | ||||||